In odd aftermath of FDA Commissioner Mark McClellan’s lecture, NCI Director Andrew von Eschenbach forwards the commissioner’s thank-you note to 3,000 NCI staff. The email blast follows FDA’s return of NCI’s gift to McClellan.
Also in this 8-page issue: NCI informatics project caBIG will “rapidly accelerate” cancer research, von Eschenbach says.
NCI plans 18 percent budget cuts for large R01s, smaller cuts to other research project grants. NCI treatment division director Ellen Feigal accepts position with Translational Genomics Research Institute in Phoeniz, Ariz.
In the cancer centers: San Antonio Cancer Institute gets a new director, funding commitments.
UT Health Science Center dedicates new Children’s Cancer Research Institute.
Funding opportunities listed.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
